Adderall, the brand-name mix of amphetamine salts used primarily for ADHD, was approved by the FDA in 1996. But the drug’s active ingredients have a much longer history, stretching back nearly a century to a biochemist’s lab bench in 1929. The name “Adderall” is relatively young; the molecule it delivers is one of the oldest psychiatric drugs still in widespread use, and its journey from decongestant research to Schedule II stimulant touches on wartime pharmacology, weight-loss pills, evolving diagnostic criteria, and a modern supply crisis.
Amphetamine’s Discovery in the Late 1920s
The story starts not with attention or behavior but with stuffy noses. In 1929, a biochemist named Gordon Alles was searching for a substitute for ephedrine, which was used as a decongestant and bronchodilator but was expensive and hard to source. His experiments led him to synthesize and test beta-phenyl-isopropylamine, the compound that would soon be called amphetamine. Alles published his first clinical results that same year and received a patent on its orally active salts in 1932.1PubMed Central. America’s First Amphetamine Epidemic 1929–1971: A Quantitative and Qualitative Retrospective With Implications for the Present
Almost immediately, a pharmaceutical company called Smith, Kline and French saw commercial potential. Possibly inspired by Alles’s work, the Philadelphia firm investigated the base form of amphetamine, patented it in 1933, and released it as the Benzedrine Inhaler, a simple capped tube containing 325 milligrams of oily amphetamine base.1PubMed Central. America’s First Amphetamine Epidemic 1929–1971: A Quantitative and Qualitative Retrospective With Implications for the Present The device was sold over the counter for nasal congestion. It did not take long for people to notice that Benzedrine did a lot more than clear sinuses. Throughout the 1930s and 1940s, researchers explored its effects on attention, cognition, mood, and appetite, and by the late 1940s amphetamine had achieved broad medical success as both an antidepressant and a diet medication.2PubMed. Amphetamine-Type Stimulants: The Early History of Their Medical and Non-Medical Uses
From Wartime Stimulant to Children’s Medicine
World War II gave amphetamine its largest early proving ground. Both Allied and Axis forces distributed stimulant pills to soldiers to fight fatigue and boost alertness during long missions. Benzedrine tablets saw heavy use among American and British troops, while German forces relied on methamphetamine, sold under the brand name Pervitin.3PubMed. Brief history of the medical and non-medical use of amphetamine-like psychostimulants Millions of tablets were distributed, and when the war ended, a generation of veterans had firsthand experience with the drug’s stimulating effects. Postwar demand helped fuel a growing civilian market.
Meanwhile, a quieter but eventually more consequential line of research was developing. In 1937, a physician named Charles Bradley gave Benzedrine to children at a psychiatric hospital in Rhode Island and noticed a paradoxical calming effect on their behavior. That observation was largely ignored by the broader medical community for years, but clinicians at a few centers continued experimenting. By 1950, researchers at a children’s psychiatric hospital had accumulated twelve years of experience using both Benzedrine (a racemic mixture of amphetamine) and Dexedrine (the purified dextro form) to treat behavior disorders in children, covering hundreds of patients.4Pediatrics. BENZEDRINE® AND DEXEDRINE® IN THE TREATMENT OF CHILDREN’S BEHAVIOR DISORDERS The work was modest in scale, but it planted the seed for what would eventually become the standard pharmacological approach to ADHD.
Obetrol Becomes Adderall
For decades after the war, amphetamines were prescribed for an enormous range of conditions, from depression and fatigue to weight loss. One of the products on the market was Obetrol, a blend of amphetamine salts originally approved as a diet pill in the 1960s. Obetrol contained a mix of amphetamine and dextroamphetamine salts in a specific ratio, and it had a modest commercial life until Rexar Pharmacal acquired the rights in the 1980s.
In the early 1990s, Richwood Pharmaceuticals reformulated Obetrol and rebranded it for a completely different purpose: treating attention deficit disorder. The new product was named Adderall, reportedly a contraction of “A.D.D. for all.” The FDA approved it in 1996 as an immediate-release tablet for ADHD. The timing was significant. Diagnostic awareness of ADHD in children was surging during the 1990s, and Adderall entered a market that was hungry for treatment options beyond methylphenidate (Ritalin), which had dominated for years. Shire Pharmaceuticals later acquired Richwood and became the company most closely associated with the Adderall brand.
The prescribing landscape during this period was changing fast. In Michigan alone, amphetamine prescribing rates for children and adolescents rose dramatically through the 1990s, with increases ranging from roughly 380 percent for the youngest children to over 800 percent for teenagers during an eight-year study window.5PubMed. Trend and area variation in amphetamine prescription usage among children and adolescents in Michigan These were not small shifts. The growth reflected both rising diagnoses and growing physician comfort with stimulant medications for ADHD.
The Extended-Release Capsule
One of the practical problems with Adderall’s original immediate-release tablets was that they wore off relatively quickly, often requiring a second dose midday. For school-age children, that meant a trip to the nurse’s office, which was stigmatizing and logistically annoying. For adults, it meant remembering a lunchtime pill. Shire’s answer came in 2001 with Adderall XR, an extended-release capsule designed to last around twelve hours on a single morning dose.
The XR capsule uses a bead-based delivery system. Half the pellets inside release their dose immediately upon ingestion, while the other half are coated to delay release by about four hours. The capsule maintains the same 3-to-1 ratio of dextroamphetamine to levoamphetamine as the original immediate-release tablets, and the pharmacokinetic profile of a single 20 mg XR capsule is comparable to taking two 10 mg immediate-release tablets spaced apart. Onset is fast, within about an hour and a half, and coverage extends through the school or work day.6PubMed Central. Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD The convenience factor made XR enormously popular and helped Adderall become the dominant amphetamine brand in the United States.
Lisdexamfetamine and the Prodrug Approach
By the mid-2000s, concerns about stimulant misuse were growing. College students were buying and sharing Adderall pills, and the drug had a well-known street value. One pharmaceutical strategy to reduce abuse potential was the prodrug concept: designing a molecule that is pharmacologically inactive until the body metabolizes it. Shire developed lisdexamfetamine dimesylate, marketed as Vyvanse, which the FDA approved in 2007. It was the first prodrug stimulant.7PubMed Central. Lisdexamfetamine dimesylate: the first prodrug stimulant
Lisdexamfetamine is essentially dextroamphetamine bonded to the amino acid lysine. The bond is cleaved during digestion, which means the active drug is released gradually as the compound is metabolized. The result is a slower peak and lower maximum blood concentration compared to swallowing an equivalent dose of immediate-release dextroamphetamine, which translates to a smoother onset and, at least in theory, less of the euphoric rush that makes a drug attractive for recreational use.8PubMed Central. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy Whether the reduced abuse potential is clinically meaningful in practice has been debated, but the pharmacokinetic data consistently shows a flatter curve.9PubMed. Comparative pharmacology and abuse potential of oral dexamphetamine and lisdexamfetamine-A literature review
Vyvanse quickly carved out a large share of the ADHD market and, for years, was protected by a patent that kept generics off the shelves. That patent expired in early 2023, with a pediatric exclusivity extension pushing the final date to August 2023.10JAMA Health Forum. Manufacturing Supply Chains and Imports in the ADHD Drug Shortage Multiple generic manufacturers entered the market afterward, which has started to bring down costs for patients who had been paying brand-name prices.
The DSM-5 and the Rise of Adult Diagnoses
For most of Adderall’s existence, ADHD was thought of primarily as a childhood condition that many people outgrew. The diagnostic criteria reflected that framing. When the DSM-5 was published in 2013, it made a notable change: adults could now qualify for a diagnosis with fewer symptoms than the previous edition required. In one study comparing the two sets of criteria, the new cutoff produced a 65 percent increase in the number of adults meeting the symptom threshold.11PubMed. New DSM-5 criteria for ADHD – Does it matter?
That change did not happen in a vacuum. Growing public awareness, driven partly by social media and partly by decades of research showing that ADHD persists into adulthood for many people, meant more adults were seeking evaluation. The DSM-5 revision lowered the diagnostic bar at a moment when demand was already climbing. The result was a substantial expansion of the adult ADHD patient population, which in turn drove new stimulant prescriptions.
Nonmedical Use on College Campuses
Adderall’s reputation as a “study drug” emerged alongside its clinical growth. By the late 2000s, nonmedical use of prescription stimulants among college students was well-documented in the United States, with students obtaining pills from friends or buying them to pull all-nighters before exams.12PubMed Central. Nonmedical prescription stimulant use among college students: why we need to do something and what we need to do The phenomenon was not unique to American universities; researchers in Australia and other countries also documented it, though the prevalence was best studied in the U.S.13PubMed Central. Non-medical prescription stimulant use to improve academic performance among Australian university students: prevalence and correlates of use
The irony is worth noting. Amphetamine was originally a mass-market drug available without prescription, sold as a nasal inhaler. Then it became tightly regulated under the Controlled Substances Act of 1970 as a Schedule II substance. Then it re-entered popular culture as an illicit study aid, circulated hand-to-hand on campuses. The molecule’s cultural role has swung back and forth between mainstream medicine and off-label subculture for nearly a century.
COVID, Telehealth, and the Shortage
The COVID-19 pandemic reshaped how stimulants were prescribed almost overnight. When lockdowns shuttered clinics in early 2020, emergency federal telehealth flexibilities allowed clinicians to prescribe Schedule II controlled substances, including Adderall, without an in-person evaluation for the first time. Among Medicaid and CHIP enrollees, the shift was dramatic: telehealth-only stimulant initiations jumped by about 25 per 100,000 enrollees per month, while in-person initiations dropped by about 54 per 100,000.14PubMed. Trends In Telehealth Initiation Of Prescription Stimulants For Child And Adult Enrollees In Medicaid And CHIP During COVID-19 Telehealth largely compensated for the loss of in-person visits rather than adding entirely new demand on top of it, and total initiation rates in this population actually remained below pre-pandemic levels through the end of 2022.
The pattern looked different for adults versus children. During the pandemic, new stimulant prescriptions for adults increased while those for children dipped slightly. For children aged 2 to 17, monthly stimulant initiations stayed essentially flat overall, but adult initiations rose from a pre-pandemic average of about 27 per 100,000 enrollees to 33.15PubMed Central. Trends in Use of Telemedicine for Stimulant Initiations among Children and Adults Several telehealth-first companies, some of which faced scrutiny for lax diagnostic practices, made it easy for adults to get evaluated and prescribed from their couches. The increased adult demand, combined with existing supply constraints, set the stage for a national shortage.
By late 2022, the FDA officially declared an Adderall shortage. The underlying problem was partly one of quotas and manufacturing. The DEA sets annual production caps for Schedule II drugs, and actual retail distribution of amphetamine in the United States was running at only about 70 percent of the allotted production quota in 2022, even before exports were factored in.16JAMA Health Forum. Manufacturing Supply Chains and Imports in the ADHD Drug Shortage The shortage was not caused by the DEA capping production too low; manufacturers simply were not making enough to fill the quota they already had. Supply-chain disruptions, raw material delays, and the exit or slow start of some generic manufacturers all played roles. Patients faced months of hunting from pharmacy to pharmacy, and the shortage persisted well into 2023 and beyond.
Cardiovascular Concerns with Long-Term Use
As more adults take Adderall for years or even decades, questions about long-term safety have sharpened. The most discussed risk involves the heart. Amphetamines increase heart rate and blood pressure by stimulating the sympathetic nervous system, and chronic exposure raises concerns about cumulative cardiovascular damage. Case reports and small studies have linked prolonged amphetamine-dextroamphetamine use to cardiomyopathy, a condition involving structural or functional abnormalities of the heart muscle. Proposed mechanisms include increased oxidative stress, sustained sympathetic overactivation, and direct toxicity to heart muscle cells.17PubMed Central. Prolonged Amphetamine-Dextroamphetamine Use: An Unrecognized Cause of Cardiomyopathy
The word “unrecognized” in the research literature is telling. Most prescribing guidelines focus on short-term hemodynamic effects like elevated blood pressure and tachycardia, with routine monitoring recommended at follow-up visits. The possibility that years of use might slowly remodel the heart has received far less attention, in part because large-scale long-term outcome studies of stimulant-treated adults are still sparse. For someone who started Adderall in elementary school and is now thirty, the cumulative exposure is substantial, yet the evidence base for outcomes at that timescale is thin. Clinicians generally advise periodic cardiovascular screening for long-term users, but the specific intervals and methods remain loosely defined.
Why the Name “Adderall” Sticks Around
Generic mixed amphetamine salts have been available since Adderall’s original patents expired in the early 2000s, and most prescriptions filled today are generic. Yet “Adderall” persists as a cultural shorthand for prescription stimulants the way “Kleenex” persists for facial tissue. Part of this is timing: the brand launched during the period when ADHD awareness exploded, and it became embedded in the cultural conversation about attention, productivity, and academic performance. Part of it is the sheer recognizability of the name in a way that “mixed amphetamine salts, 20 mg” will never be.
That cultural stickiness has consequences. When people talk about an “Adderall epidemic” or the “Adderall shortage,” they are usually talking about the entire class of prescription amphetamine products, not one brand. The conflation sometimes muddles public understanding of what is actually happening. The 2022 shortage, for instance, affected generic mixed amphetamine salts and lisdexamfetamine simultaneously, but media coverage overwhelmingly used “Adderall” as the umbrella term. For patients, the practical result was the same either way: empty shelves and long waits. But the specifics of which supply chains broke, and why, were different for different products.
Nearly a hundred years after Gordon Alles first tested amphetamine as a possible cold remedy, the molecule remains at the center of American psychiatry’s most contested debates. It treats a condition whose boundaries keep shifting. It fuels a black market on college campuses while also improving daily functioning for millions of people with a legitimate diagnosis. Its supply chain is governed by a production-quota system designed in 1970 that was never built for a patient population this large. The drug itself is old. The questions it raises keep renewing.